TGA strengthens warnings on antibiotic side effects GPs have been asked to use fluoroquinolones ‘judiciously’, as the Administration rolls out more prominent warnings.
Wegovy approved for cutting cardiovascular disease risk The TGA has approved semaglutide (sold as Wegovy) as an adjunct to standard of care therapy to reduce the risk of major adverse cardiovascular events in overweight and obese adults.
ADHD med shortages ‘a merry-go-round you just can’t predict’ The new school year has coincided with another series of shortages, forcing patients and prescribers to rethink their options.
‘A big difference’: Poisons Standard change brings hope Reduced paracetamol pack sizes are now in force, as a new report highlights the number of children hospitalised due to preventable medicine-related issues.
Most GPs discover medication shortages through patients: Poll A new survey highlights the urgency of improving measures to communicate supply chain disruptions, with patients increasingly feeling an impact.
TGA updates montelukast safety information Extra information is being added to all products to highlight the existing warnings, as a ‘reminder to watch out’ for side effects.
Extent of non-compliant medicinal cannabis clinics revealed New research has highlighted the need for more stringent monitoring and regulation when it comes to advertising practices around the prescribing of medicinal cannabis products.
Quetiapine shortage ‘frankly unacceptable’ Some doses of the antipsychotic medication could be in shortage until July, leaving both patients and GPs ‘alarmed’.
‘Too little, too late’: An investigation into medication shortages How are medication shortages affecting GPs and their patients? Calls are being made to change how they are being managed and communicated.
Ozempic shortage extended The manufacturer has informed the TGA that supply will be limited until 31 December 2025, with GPs labelling it an ‘ongoing disappointment’.